ACM
ALNY icon

Aster Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aster Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-78
Closed -$35.6K – 1075
2025
Q3 		$35.6K Buy
+78
New +$31.8K 0.02% 565
2025
Q2 		– Sell
-2,451
Closed -$605K – 1005
2025
Q1 		$605K Buy
+2,451
New +$630K 0.11% 248
2024
Q4 		– Sell
-3,558
Closed -$979K – 1099
2024
Q3 		$979K Buy
+3,558
New +$926K 0.21% 120

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Aster Capital Management's ALNY Position: Q4 2025 in Review

Aster Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 78 shares — an estimated $35.6K sold.

Aster Capital Management first reported a position in ALNY in Q3 2024 and held it in 3 quarters. The position peaked at $979K in Q3 2024. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Aster Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aster Capital Management sold 78 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $35.6K.
  • Aster Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Alnylam Pharmaceuticals position peaked at $979K in Q3 2024.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.